Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. director and CEO Rachel McMinn reported an automatic sale of common stock tied to RSU vesting. On March 26, 2026, 3,352 shares of Neurogene common stock were sold at a weighted average price of $22.0749 per share to cover tax withholding from a partially vested Restricted Stock Unit award. The award agreement required the company to sell enough shares to satisfy tax obligations, with no election by McMinn, making this a mechanistic tax-related sale rather than a discretionary open-market trade. After the transaction, she directly held 1,344,307 shares of common stock, along with additional restricted stock units scheduled to vest between February 2027 and February 2029.
Neurogene Inc. Chief Medical Officer Julie Jordan reported an open-market sale of 828 shares of Common Stock at a weighted average price of $21.8932 per share. According to the disclosure, this sale was mandatory and executed solely to cover tax withholding arising from a partially vested restricted stock unit (RSU).
After this transaction, Jordan reports holding 12,472 shares, including 5,600 RSUs that vest in equal annual installments on March 26, 2027 and March 26, 2028, and 4,900 RSUs that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029, all subject to continued service.
Neurogene Inc. is a clinical-stage biotech focused on genetic medicines for severe neurological diseases, led by NGN-401, a gene therapy for Rett syndrome using its proprietary EXACT transgene regulation platform and in-house AAV manufacturing.
The Phase 3 Embolden trial of NGN-401 is fully enrolled, with over half of participants dosed, and prior Phase 1/2 data showed functional gains and generally well-tolerated safety at the 1E15 vg dose. NGN-401 has received Breakthrough Therapy, RMAT and PRIME designations and was selected for the FDA’s START pilot program.
Neurogene remains pre-revenue and deeply loss-making, reporting a net loss of $90.4 million in 2025 versus $75.1 million in 2024, with an accumulated deficit of $352.6 million as of December 31, 2025. Cash, cash equivalents and short-term investments totaled $269.0 million, and management expects to need substantial additional capital as it advances clinical programs and scales its 42,000-square-foot Houston cGMP facility. As of March 18, 2026, the company had 15,574,293 common shares outstanding.
Neurogene Inc. reported a full year 2025 net loss of $90.4 million, widening from $75.1 million in 2024, as it increased investment in its Rett syndrome gene therapy program NGN-401.
Research and development expenses rose to $75.0 million from $60.9 million, and general and administrative expenses increased to $28.3 million from $22.6 million, mainly due to higher clinical trial and employee-related costs. The company ended 2025 with $269.0 million in cash, cash equivalents and short-term investments, which it expects to fund operations through the first quarter of 2028.
Clinically, Neurogene fully enrolled its Embolden registrational trial for NGN-401 in Rett syndrome, with more than half of participants dosed and dosing completion targeted for the second quarter of 2026. Interim Phase 1/2 data at the 1E15 vg dose showed multidomain, durable functional gains across motor and communication domains, with NGN-401 generally well-tolerated and no cases of hemophagocytic lymphohistiocytosis.
NGN-401 received FDA Breakthrough Therapy designation based on interim Phase 1/2 data, and the FDA confirmed commercial manufacturing scale will match clinical scale, avoiding comparability studies. Neurogene plans to begin a Process Performance Qualification campaign and present updated Phase 1/2 data, including at least 12 months of follow-up for all 10 participants, in mid-2026, while continuing early commercial-readiness and payor engagement activities.
Neurogene Inc. Chief Scientific Officer Stuart Cobb reported selling 6,797 shares of common stock in three open-market transactions on March 13, 2026. The sales occurred at prices reported as weighted averages of $20.41, $21.34, and $22.08, with detailed ranges noted in the disclosure.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2025. After these transactions, Cobb directly holds 30,497 shares, which include restricted stock units scheduled to vest between 2026 and 2029, subject to continued service.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported automatic sales of common stock tied to a restricted stock unit (RSU) vesting. On March 13, 2026, a total of 4,045 shares of Neurogene common stock were sold in three open-market transactions at weighted average prices of $20.4224, $21.2451, and $22.0195 per share.
According to the disclosure, these sales were executed under the RSU award agreement, which requires the company to sell enough shares to cover the executive’s tax withholding obligations from the March 12, 2025 vesting event, with no election by the executive. After the sales, Cvijic directly owned 105,798 common shares, in addition to multiple unvested RSU awards scheduled to vest between 2026 and 2029.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open‑market sale of 4,800 shares of common stock on February 27, 2026 under a pre‑arranged Rule 10b5‑1 plan adopted on August 18, 2025. The weighted average sale price was $25.1096 per share, with individual trades ranging from $25.00 to $25.325. After this transaction, she and her spouse jointly hold 109,843 shares, including 21,269 restricted stock units from a March 13, 2024 grant, 20,300 restricted stock units from a March 26, 2025 grant, and 22,000 restricted stock units from a February 20, 2026 grant, plus 19,200 shares held jointly.
Neurogene Inc. announced that the U.S. FDA has granted Breakthrough Therapy designation to NGN-401, its investigational, one-time AAV9 gene therapy for Rett syndrome. The designation is based on interim Phase 1/2 data as of October 30, 2025, showing clinically meaningful, durable functional improvements across multiple Rett domains with continued skill acquisition over time.
NGN-401 uses Neurogene’s proprietary EXACT™ transgene regulation technology and is delivered via intracerebroventricular administration to broadly target the brain and nervous system. The therapy is being studied in the Embolden™ registrational trial, with dosing expected to complete in the second quarter of 2026 and additional interim Phase 1/2 data planned for mid-2026. NGN-401 also holds multiple other U.S., European and U.K. regulatory designations intended to support development for this serious rare disease.